UK markets close in 4 hours 41 minutes

MDxHealth SA (0O8G.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.0198-0.1804 (-5.64%)
As of 06:16PM BST. Market open.

MDxHealth SA

CAP Business Center
Rue d’Abhooz 31 Zone Industrielle des Hauts-Sarts
Herstal 4040
32 4 257 70 21

Full-time employees300

Key executives

NameTitlePayExercisedYear born
Mr. Michael K. McGarrityCEO & Executive Director709.27kN/A1963
Mr. Ron Kalfus CPAChief Financial OfficerN/AN/A1974
Mr. Joseph Sollee J.D., LLMExecutive VP of Corporate Development & General CounselN/AN/A1965
Mr. John A. BellanoChief Commercial OfficerN/AN/A1969
Ms. Miriam ReyesExecutive Vice President of OperationsN/AN/A1973
Dr. Jason Poole Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Corporate governance

MDxHealth SA’s ISS governance QualityScore as of 1 July 2024 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.